Florbetapir Calibration to the Centiloid Scale

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

The Feasibility of Florbetapir Quantitation

NCT01946243 ·Status: COMPLETED ·Phase: PHASE4

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

NCT01703702 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

NCT02029547 ·Status: WITHDRAWN ·Phase: NA

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706 ·Status: COMPLETED ·Phase: PHASE1

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506 ·Status: COMPLETED ·Phase: PHASE2

Augmenting Flortaucipir Dosimetry Estimates

NCT02336360 ·Status: COMPLETED ·Phase: PHASE1

Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

NCT03902548 ·Status: COMPLETED ·Phase: PHASE1

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

NCT01890343 ·Status: COMPLETED ·Phase: PHASE2

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT07012993 ·Status: RECRUITING ·Phase: PHASE2

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

NCT01565356 ·Status: COMPLETED ·Phase: NA

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

NCT01020838 ·Status: COMPLETED ·Phase: PHASE3

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

NCT04468347 ·Status: COMPLETED ·Phase: PHASE1

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

NCT01400425 ·Status: COMPLETED ·Phase: PHASE3

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

NCT00857415 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Reader Training Processes

NCT02051790 ·Status: COMPLETED ·Phase: PHASE4

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

NCT01565291 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

NCT01138111 ·Status: COMPLETED ·Phase: PHASE1

Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)

NCT01607476 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

NCT00702143 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

NCT01565382 ·Status: COMPLETED ·Phase: PHASE3